Article
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Journal of the National Cancer Institute - 15 Jan 1997
Grignon D J, Caplan R, Sarkar F H, Lawton C A, Hammond E H, Pilepich M V, Forman J D, Mesic J, Fu K K, Abrams R A, Pajak T F, Shipley W U, Cox J D
Abstract excerpt
BACKGROUND: The p53 tumor suppressor gene (also known as TP53) is one of the most frequently mutated genes in human cancer. Several studies have shown that p53 mutations are infrequent in prostate cancer and are associated with advanced disease. PURPOSE: We assessed the prognostic value of identi...
Topics
- Adenocarcinoma
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
- Chemotherapy, Adjuvant
- Clinical Trials, Phase III as Topic
- Disease Progression
- Disease-Free Survival
- Flutamide
- Gene Expression Regulation, Neoplastic
- Genes, p53
- Goserelin
- Humans